Prognostic Value of MMP-9 in Ovarian Cancer: A Meta-analysis
Prognostic Value of MMP-9 in Ovarian Cancer: A Meta-analysis
复制标题
DOI：
10.7314/apjcp.2013.14.7.4107
复制
发表时间：
2013-01-01
影响因子：
--
通讯作者：
Yan, Jun
中科院分区：
文献类型：
--
作者：
Li, Li-Na;Zhou, Xin;Yan, Jun
目的：基质金属蛋白酶-9（MMP-9）在肿瘤细胞侵袭过程中发挥重要作用。虽然它在卵巢癌中的研究频繁，但其对预后的影响仍不明确。本研究的目的是更准确地估计其预后意义。方法：检索Pubmed、Embase、OVID、Sciencedirect和CBM数据库，筛选符合条件的研究。使用固定效应或随机效应模型的研究汇总了具有95%置信区间（95% ci）的风险比（hr）或优势比（ORs）。我们还进行了亚组分析。结果：纳入30项研究（n=2552例患者），重点关注MM-9的预后或表达。卵巢癌患者MMP-9表达升高与预后不良相关（HR=1.68, 95% CI 1.09-2.59, p=0.02）。MMP-9在卵巢癌中的表达明显高于非恶性肿瘤(OR=11.46, 95% CI 8.47 ~ 15.50， P
Objective: Matrix metalloproteinase-9(MMP-9) plays an important role in tumor cell invasion. Although it has been studied frequently in ovarian cancer, its prognostic impact is still equivocal. The aim of this study was to more precisely estimate its prognostic significance. Method: We searched Pubmed, Embase, OVID, Sciencedirect and CBM databases to identify eligible studies. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs) were pooled across studies using fixed-effects or random-effects models. We also performed subgroup analysis. Results: 30 studies (n=2552 patients) focusing on prognosis or expression of MM-9 were included. Increased expression of MMP-9 was associated with poor prognosis in ovarian cancer patients (HR=1.68, 95% CI 1.09-2.59, p=0.02). Besides, MMP-9 expression in ovarian cancer was significantly higher than non-malignant tumors (OR=11.46, 95% CI 8.47-15.50, P